Given the importance of developing prognostic biomarkers to predict response to therapy, additional studies evaluating the potential of SFRP2 as a clinical prognostic or predictive biomarker of response in osteosarcoma patients are warranted. Here, SFRP2 is linked to osteosarcoma.